KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities
Cancers · 13.11.2026 · 18 (22) · 3635
DOI: 10.3390/cancers18223635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 13.11.2026. Verfasst von Sofia G. Garza und 2 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UT SPORE in the Lung Cancer Enhancement—Development Research Program grant, 2024, Rexanna’s Foundation—Lance Bertrand Research Grant, 2024, Rexanna’s Foundation—Bruce Campbell Family Research Grant, 2024.
Abstract (Originalsprache)
Background/Objectives: Resistance to currently available KRAS inhibitors presents a major therapeutic challenge in non-small cell lung cancer (NSCLC). The purpose of this review is to describe the various mechanisms of resistance to KRAS inhibitors, including the activation of an epithelial-to-mesenchymal transition (EMT) program, tumor microenvironment modulation, and the rewiring of KRAS-addicted cancer cells towards other signaling pathways that promote growth and proliferation amidst KRAS inhibition.
Results
Through a narrative review of recent and landmark studies in the field of KRAS inhibitor resistance, we summarize the primary non-genetic mechanisms of resistance to KRAS inhibitors as follows: receptor tyrosine kinase-mediated induction of both wild-type and mutant KRAS and the activation of several bypass signaling pathways, such as PI3K/AKT, Gas6/AXL, and YAP/TEAD/Hippo.
Conclusions
We conclude that no single non-genetic driver of resistance is responsible for all cases of KRAS inhibitor resistance; rather, effective therapeutic strategies may also be informed by the tumor co-mutational status and the transcriptional phenotype of the tumor, including a mesenchymal or highly plastic cell state.
Förderung
- UT SPORE in the Lung Cancer Enhancement—Development Research Program grant, 2024
- Rexanna’s Foundation—Lance Bertrand Research Grant, 2024
- Rexanna’s Foundation—Bruce Campbell Family Research Grant, 2024
- CPRIT
- Isaiah J. Fidler Professorship
Zitieren
APA
Garza, S. G., Kundu, S. T., & Gibbons, D. L. (2026). KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities. Cancers, 18(22), 3635. https://doi.org/10.3390/cancers18223635
Vancouver
Garza SG, Kundu ST, Gibbons DL. KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities. Cancers. 2026;18(22):3635. doi:10.3390/cancers18223635
BibTeX
@article{Garza2026,
author = {Garza, Sofia G. and Kundu, Samrat T. and Gibbons, Don L.},
title = {KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3635},
doi = {10.3390/cancers18223635}
}
EUVIMED